PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
暂无分享,去创建一个
E. di Tomaso | P. Aimone | C. Massacesi | P. Urban | C. Germa | C. Quadt | L. Trandafir | N. Fretault | B. Dharan | R. Tavorath | S. Hirawat | E. Tomaso | Bharani Dharan